Aducanumab to Be Discontinued as an Alzheimer’s Treatment
Aducanumab (Aduhelm®), which received accelerated approval as a treatment for Alzheimer's disease from the U.S. Food and Drug Administration (FDA) in 2021, will be discontinued by its manufacturer (Biogen) in 2024.
FDA’s Decision to Approve New Treatment for Alzheimer’s Disease
FDA approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans, using the Accelerated Approval pathway.
Aducanumab - StatPearls - NCBI Bookshelf
Feb 26, 2024 · This activity focuses on the prescription of aducanumab, a groundbreaking amyloid ß-directed monoclonal antibody for the treatment of Alzheimer disease (AD). Granted accelerated approval by the United States Food and Drug Administration (FDA) in June 2021, aducanumab is the first AD treatment to receive formal regulatory clearance since 2003.
Aducanumab (marketed as Aduhelm) Information | FDA
Aduhelm is an amyloid beta-directed antibody indicated to treat Alzheimer’s disease. Aduhelm is approved under the accelerated approval pathway, which provides patients with a serious disease ...
Aduhelm | ALZFORUM
Jan 3, 2016 · Aducanumab dose-dependently reduced amyloid deposition in six cortical regions of the brain. The effect was large: After one year, the highest dose appeared to have reduced cortical amyloid close to the cut point of positivity.
Aducanumab: First Approval - PubMed
Aducanumab (aducanumab-avwa; Aduhelm™) is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid β. It has been co-developed by Biogen and Eisai under license from Neurimmune for the treatment of Alzheimer's disease.
FDA Grants Accelerated Approval for Alzheimer’s Drug | FDA
Jun 7, 2021 · Today, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans.
The antibody aducanumab reduces Aβ plaques in Alzheimer’s …
Aug 31, 2016 · Aducanumab is a recombinant human monoclonal antibody that selectively targets the amyloid-β (Aβ) peptide aggregates thought to play a part in the neurodegenerative process in Alzheimer's...
Aducanumab in Alzheimer's disease: A critical update - PubMed
Jul 27, 2023 · Aducanumab, as a monoclonal antibody, has shown promising results in inhibiting amyloid plaque formation, which is the primary pathological feature of AD. This review explores the signaling pathways and molecular mechanisms through which aducanumab effectively prevents disease pathogenesis in AD.
What to Know About the Alzheimer Drug Aducanumab (Aduhelm)
What Is Aducanumab? The FDA recently approved aducanumab (Aduhelm) for people with mild symptoms of Alzheimer disease, such as individuals who are still independent in basic daily functioning. It reduced brain amyloid plaque (protein deposits), a main feature of …
- Some results have been removed
Skip to content